Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Cathia Soulie und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pit…. Hauptthemen laut MEDLINE: HIV Infections, HIV Integrase Inhibitors, Drug Resistance, Viral, HIV-1. Die Arbeit nennt 19 Literaturangaben. Gefördert von: ANRS-MIE.
Abstract (Originalsprache)
Background
The aim of this study was to evaluate changes in prevalence of resistance to integrase strand transfer inhibitors (INSTIs) in relation to changes in their use over 16 years in people living with HIV (PLWHIV) treated with antiretrovirals (ARVs) and in virological failure. Materials and methods We analysed the use of different INSTIs (for ≥3 months during the study year) in ARV-treated PLWHIV in an academic centre and the HIV INSTI resistance profiles in RNA in case of virological failure (2008–24; analysed using the ANRS-MIE algorithm v33).
Results
During the studied period (2008–24), INSTI use increased from 3.3% to 71.2%. Raltegravir use peaked at 21.5% in 2013 and then declined to 2.5% in 2024. Elvitegravir followed a similar trend, increasing to 15.7% in 2018 and then decreasing to 1.5% in 2024. Dolutegravir increased steadily from 6.3% in 2014 to 39.3% in 2023 and bictegravir from 2.0% in 2018 to 28.0% in 2024. Cabotegravir, first noted in 2020 (0.3%), will reach 3.8% in 2024. The proportion of patients with INSTI-resistant viruses was initially high for raltegravir (47.8% in 2008), before decreasing. By 2024, resistance was 2.7% for dolutegravir, cabotegravir and bictegravir, but remained higher for raltegravir (8.5%) and elvitegravir (9.8%).
Conclusions
Although the use of INSTIs has increased over time with differences in the duration of use, we did not observe a corresponding increase in the proportion of ARV-treated PLWHIV who experienced virological failure with INSTI-resistant viruses during the study period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratoire de virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, 45-83 bd de l'Hôpital, Paris, France.
- Service de maladies infectieuses, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
ORCID-Profile: Cathia Soulie, Basma Abdi, Marc Wirden, Romain Palich, Valérie Pourcher
Förderung
- ANRS-MIE
Zitieren
APA
Soulie, C., Agher, R., Fauchois, A., Abdi, B., Wirden, M., Teyssou, E., Sayon, S., Katlama, C., Valantin, M. A., Tubiana, R., Schneider, L., Faycal, A., Palich, R., Pourcher, V., Marcelin, A. G., & Calvez, V. (2026). Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf454
Vancouver
Soulie C, Agher R, Fauchois A, Abdi B, Wirden M, Teyssou E, et al. Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf454
BibTeX
@article{Soulie2026,
author = {Soulie, Cathia and Agher, Rachid and Fauchois, Antoine and Abdi, Basma and Wirden, Marc and Teyssou, Elisa and Sayon, Sophie and Katlama, Christine and Valantin, Marc-Antoine and Tubiana, Roland and Schneider, Luminita and Faycal, Antoine and Palich, Romain and Pourcher, Valérie and Marcelin, Anne-Geneviève and Calvez, Vincent},
title = {Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf454}
}
EUVIMED